DGA Parker, HM Brereton, S Klebe, DJ Coster … - British Medical Journal, 2009 - bjo.bmj.com Aim: Topical glucocorticosteroids are administered to virtually every corneal
transplant recipient, but irreversible immunological rejection remains the
leading cause of graft failure. Ex vivo gene therapy of the donor cornea ... Related articles - All 3 versions
- ►bloodjournal.org K Narumi, M Suzuki, W Song, MAS Moore, RG … - Blood, 1998 - Am Soc Hematology For many in vivo gene therapy clinical applications, it is desirable to control
the expression of the transferred transgene using pharmacologic agents. To
evaluate the feasibility of accomplishing this using corticosteroids, ... Cited by 9 - Related articles - BL Direct - All 4 versions
- Free from Publisher K Narumi, A Kojima, RG Crystal - American journal of respiratory cell and molecular …, 1998 - ncbi.nlm.nih.gov To evaluate the concept that in vivo transfer of perforin complementary DNA
(cDNA) will suppress tumor growth, we constructed an adenovirus vector
(AdGRE.PFP) carrying perforin cDNA driven by the glucocorticoid response ... Cited by 11 - Related articles - BL Direct - All 3 versions
DGA Parker, C Kaufmann, HM Brereton, DS … - Gene Therapy, 2007 - nature.com Gene therapy of the cornea shows promise for modulating corneal transplant
rejection but the most appropriate vector for gene transfer has yet to be
determined. We investigated a lentiviral vector (LV) for its ability to ... Cited by 12 - Related articles - BL Direct - All 4 versions
- ►iovs.org N Gong, U Pleyer, K Vogt, I Anegon, A Flugel, … - Investigative ophthalmology & visual science, 2007 - ARVO 1 From the Department of Ophthalmology and the 3 Institute of Medical
Immunology, Charité-University Medicine, Berlin, Germany; the 2 Institute of
Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong ... Cited by 13 - Related articles - BL Direct - All 3 versions
IA Halaby, SP Lyden, MG Davies, E Roztocil, … - Molecular Therapy, 2002 - Elsevier Vascular endothelial growth factor (VEGF) is a potent neovascular inducer. Gene
therapeutic delivery of a plasmid DNA encoding VEGF has been shown to impart
collateral vessel development in animal models of hindlimb ischemia. ... Cited by 14 - Related articles - BL Direct - All 5 versions
RN Barcia, MR Dana, A Kazlauskas - American Journal of Transplantation, 2007 - interscience.wiley.com Corneal transplants normally enjoy a high percentage of survival, mainly because
the eye is an immune-privileged site. When allograft failure occurs, it is most
commonly due to rejection, an immune-mediated reaction that targets the ... Cited by 17 - Related articles - BL Direct - All 3 versions
- ►jimmunol.org S Klebe, DJ Coster, PJ Sykes, S Swinburne, P … - The Journal of Immunology, 2005 - Am Assoc Immnol Immunological rejection is the major cause of human corneal allograft failure.
We hypothesized that local production of IL-4 or the p40 subunit of IL-12 (p40
IL-12) by the grafted cornea might prolong allograft survival. Replication- ... Cited by 18 - Related articles - All 4 versions
D Watson, MJ Noble, GN Dutton, JM Midgley, … - Archives of Ophthalmology, 1988 - archopht.highwire.org Tropical corticosteroids are widely -*- used in ocular therapy. Regimens for
their use are based on clinical experience and data obtained from animal
experimentation.1" Little in¬ formation is available about the con¬ ... Cited by 20 - Related articles - All 3 versions
R Koldej, P Cmielewski, A Stocker, DW … - Journal of Gene Medicine, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 21 - Related articles - BL Direct - All 4 versions
